Waxman-Hatch Generic Drug Law Architect Returns To HHS As Daschle’s Deputy
This article was originally published in The Pink Sheet Daily
Executive Summary
Bill Corr was one of the architects of the ANDA/patent restoration deal behind the Waxman/Hatch legislation in 1984 - and, a quarter century later, is well positioned to make sure follow-on biologics find a place in health reform.
You may also be interested in...
Tobacco Wars Could Burn Cleanly For PhRMA
Renewed efforts to regulate tobacco are a safe issue for the drug industry: PhRMA can easily be on the side of more regulation, and it takes some of the spotlight off of drug safety.
Torti's Next Hundred Days: Active, Not Just Acting FDA Commissoner
FDA's Chief Scientist will continue to push for outside academic collaborations during his "short time" atop the agency; fall letter on follow-on biologics could draw closer reading.
Tobacco Wars Could Burn Cleanly For PhRMA
Renewed efforts to regulate tobacco are a safe issue for the drug industry: PhRMA can easily be on the side of more regulation, and it takes some of the spotlight off of drug safety.